![]() However, although participants randomized to the HIGH dose group did not have improved glycemic control, they had better glycemic control than participants randomized to the PL group. It was unexpected that the improved glycemic control seen in the MOD dose group was not seen in the HIGH dose group. Insulin AUC increased significantly over time (main effect, p < 0.02), whereas ISI decreased significantly over time (main effect, p < 0.03).Īs anticipated, a moderate dose of CrPic was associated with improved glycemic control, whereas PL was associated with decreased glycemic control. Results revealed a significant group and time interaction (p < 0.04) for glucose AUC, with glucose AUC increasing significantly in the PL group (p < 0.02) but decreasing significantly in the MOD group (p < 0.03) at 6 months. Fixed effects models were used to estimate mean change in glucose area under the curve (AUC), insulin AUC, and insulin sensitivity index (ISI). Participants completed an oral glucose tolerance test (OGTT) at baseline, 3 months, and 6 months. In this double-blinded randomized pilot trial, participants (N = 24) were randomized to high (HIGH, 1000 mcg/day, n = 8) or moderate (MOD, 600 mcg/day, n = 9) dose of CrPic or placebo (PL, n = 7) for 6 months. The purpose of this study was to evaluate whether chromium picolinate (CrPic) supplementation improves glucose regulation in overweight individuals with binge-eating disorder (BED). ![]() ![]() Chromium treatment has been shown to improve glucose regulation in some populations. ![]()
0 Comments
Leave a Reply. |